GRAIL (GRAL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.34
- Estimate
- -$1.99
- Surprise
- +33.0%
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
GRAIL (GRAL) reported a narrower loss than forecast — adjusted EPS of -$1.34 against the -$1.99 estimate (a 33.0% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates GRAL Sell at 4.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +33.0% surprise compares with a +25.8% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: Galleri
- Concentration risk — Pipeline: Galleri PMA
- Target reached (-19.7% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $143.66
- Stop
- $133.60
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
GRAL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $6.42B
- P/E (fwd)
- -17.4
- 52-week range
- $41.50–$166.47
- Off 52-week high
- 13.7%
- RSI (14)
- 54
- Volume vs avg
- 0.84×
- Score today
- 4.9/10